{
    "clinical_study": {
        "@rank": "122808", 
        "arm_group": {
            "arm_group_label": "VIS410", 
            "arm_group_type": "Experimental", 
            "description": "VIS410 administered as a single infusion with ascending dose-escalation ranging from 2 to 50 mg/kg"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the safety, tolerability, immunogenicity and\n      pharmacokinetics of single escalating doses of VIS410 in healthy volunteers."
        }, 
        "brief_title": "A Study of VIS410 to Assess Safety and Pharmacokinetics", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Influenza", 
        "condition_browse": {
            "mesh_term": "Influenza, Human"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy volunteers\n\n          -  Body mass index between 18 and 33 kg/m2, inclusive\n\n          -  Normal labs\n\n          -  Volunteers agree to use acceptable contraceptive measures\n\n        Exclusion Criteria:\n\n          -  Prior receipt of antibody or biologic therapy\n\n          -  History of cancer, heart disease, diabetes, respiratory condition (eg asthma),\n             autoimmune disorder, blood dyscrasias\n\n          -  Any chronic condition requiring daily prescription or over the counter medication\n\n          -  History of a previous severe allergic reaction\n\n          -  Drug or alcohol abuse within previous 12 months\n\n          -  Positive serology for human immunodeficiency virus (HIV) antibody, hepatitis C virus\n             (HCV) antibody or hepatitis B surface antigen (HBsAg)\n\n          -  Positive pregnancy test\n\n          -  Breast feeding\n\n          -  Positive drug or alcohol test at screening or check-in\n\n          -  Receipt of licensed vaccine (within 30 days) or other investigational product within\n             30 days or 5 half-lives, whichever is longer, before study product administration"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 21, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02045472", 
            "org_study_id": "VIS-C001"
        }, 
        "intervention": {
            "arm_group_label": "VIS410", 
            "intervention_name": "VIS410", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Antibodies, Monoclonal"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Influenza", 
            "Monoclonal antibody"
        ], 
        "lastchanged_date": "May 21, 2014", 
        "location": {
            "contact": {
                "last_name": "J K Berg, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Minneapolis", 
                    "country": "United States", 
                    "state": "Minnesota", 
                    "zip": "55404"
                }, 
                "name": "DaVita Clinical Research"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Open-Label, Dose-Escalation Phase 1 Study in Healthy Volunteers to Evaluate the Safety and Pharmacokinetics of a Human Monoclonal Antibody (VIS410) to Influenza Type A Hemagglutinin", 
        "overall_official": {
            "affiliation": "Davita Clinical Research", 
            "last_name": "J K Berg, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Incidence of adverse events", 
            "measure": "Safety assessment", 
            "safety_issue": "Yes", 
            "time_frame": "56 days post-infusion"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02045472"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Serum concentration-time profile", 
                "measure": "Pharmacokinetic analysis", 
                "safety_issue": "No", 
                "time_frame": "56 days post-infusion"
            }, 
            {
                "description": "Detect and measure anti-drug antibodies to VIS410", 
                "measure": "Immunogenicity", 
                "safety_issue": "No", 
                "time_frame": "56 days post-infusion"
            }
        ], 
        "source": "Visterra, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Visterra, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2014", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}